TY - JOUR
T1 - Performance of a Multidisciplinary Pancreatic Cancer Conference in Predicting and Managing Resectable Pancreatic Cancer
AU - Rao, Bharat
AU - Syed, Aslam
AU - Singh, Shailendra
AU - Gulati, Abhishek
AU - Moussiade, Ghita
AU - Garg, Mrinal
AU - Sharma, Manav
AU - Morrissey, Suzanne
AU - Williams, Harry
AU - Atkinson, Donald
AU - Schiffman, Suzanne
AU - Monga, Dulabh
AU - Lupetin, Anthony
AU - Kirichenko, Alexander
AU - Mitre, Marcia
AU - Tang, Amy
AU - Dhawan, Manish
AU - Kulkarni, Abhijit
AU - Thakkar, Shyam
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objectives Surgery is the curative treatment for pancreatic ductal adenocarcinoma (PDA). Guidelines recommend utilizing a multidisciplinary pancreatic cancer conference (MDPC) in treatment; however, data are limited. The objective of this study was to assess the accuracy of an MDPC. Methods Patients with PDA presented at an MDPC were prospectively collected from April 2013 to August 2016. Patients were included if the MDPC predicted them to have resectable PDA and underwent upfront surgery. Secondary aims were to compare differences in tumor characteristics, time to surgery, and resection rates with patients prior to MDPC implementation (pre-MDPC). Results A total of 278 patients were presented at the MDPC. After excluding borderline and nonresectable cases, 91 patients were predicted as resectable on evaluation, and 70 were fit for surgery. The MDPC predicted resection in 91.4%. The MDPC had larger tumor size (32.6 vs 24.0 mm), greater proportion of stage II tumor, and a shorter time from diagnosis to resection (27.3 vs 35.5 days) compared with the pre-MDPC. Microscopically negative resections were similar between MDPC and pre-MDPC (85.9% vs 88.0%) despite advanced tumor size and stage. Conclusions The MDPC demonstrates a high resection rate. Compared with a pre-MDPC, MDPC provides shorter time to surgery and selects for advanced tumors.
AB - Objectives Surgery is the curative treatment for pancreatic ductal adenocarcinoma (PDA). Guidelines recommend utilizing a multidisciplinary pancreatic cancer conference (MDPC) in treatment; however, data are limited. The objective of this study was to assess the accuracy of an MDPC. Methods Patients with PDA presented at an MDPC were prospectively collected from April 2013 to August 2016. Patients were included if the MDPC predicted them to have resectable PDA and underwent upfront surgery. Secondary aims were to compare differences in tumor characteristics, time to surgery, and resection rates with patients prior to MDPC implementation (pre-MDPC). Results A total of 278 patients were presented at the MDPC. After excluding borderline and nonresectable cases, 91 patients were predicted as resectable on evaluation, and 70 were fit for surgery. The MDPC predicted resection in 91.4%. The MDPC had larger tumor size (32.6 vs 24.0 mm), greater proportion of stage II tumor, and a shorter time from diagnosis to resection (27.3 vs 35.5 days) compared with the pre-MDPC. Microscopically negative resections were similar between MDPC and pre-MDPC (85.9% vs 88.0%) despite advanced tumor size and stage. Conclusions The MDPC demonstrates a high resection rate. Compared with a pre-MDPC, MDPC provides shorter time to surgery and selects for advanced tumors.
KW - multidisciplinary pancreatic cancer conference
KW - outcomes
KW - pancreatic adenocarcinoma
KW - quality of care
KW - resectable pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85058606712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058606712&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001209
DO - 10.1097/MPA.0000000000001209
M3 - Article
C2 - 30451791
AN - SCOPUS:85058606712
SN - 0885-3177
VL - 48
SP - 80
EP - 84
JO - Pancreas
JF - Pancreas
IS - 1
ER -